RTVP based compositions and methods for the treatment of prostate cancer

a composition and prostate cancer technology, applied in the field of rtvp genes and associated sequences, can solve the problems of poor survival rate of late-stage carcinoma patients, and achieve the effect of reducing or shutting down rtvp expression

Inactive Publication Date: 2010-01-12
BAYLOR COLLEGE OF MEDICINE
View PDF15 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018]Another embodiment of the invention is directed to nucleic acid sequences that comprise the anti-sense of the RTVP gene or representative porti

Problems solved by technology

Despite the advances made in achieving a pharmacologic orchiectomy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • RTVP based compositions and methods for the treatment of prostate cancer
  • RTVP based compositions and methods for the treatment of prostate cancer
  • RTVP based compositions and methods for the treatment of prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Identification of mRTVP-1 as a p53 Target Gene

[0065]Over the last decade, numerous studies have established p53 mutations as being paramount to the development and progression of various malignancies. The p53 tumor suppressor protein has been associated with various antitumor activities that include growth suppression, apoptosis, and anti-angiogenic activities. The majority of human tumor mutations decrease the sequence-specific DNA binding and transcriptional activity of the p53 protein 26. Today the large and expanding list of genes under the transcriptional control of p53 have been reported and it has been estimated that 200-300 genes are under the transcriptional regulation of p53 27. To date, the number of reported p53-regulated genes is approximately 80 28.

[0066]To identify prostate cancer-related genes under the transcriptional regulation of p53, a model system was established using adenoviral vector delivery of wild-type p53 compared to β-gal or an empty cassette together wi...

example 2

RTVP-1 mRNA Levels are Down-Regulated in Prostate Cancer Metastases

[0068]Having demonstrated that mRTVP-1 is induced by p53; it was next determined the mRNA expression profile of RTVP-1 in mouse and human prostate cancer tissue specimens by in situ hybridization (FIG. 3). Briefly, normal mouse prostate or prostate cancer developed in the mouse prostate reconstitution model with strain 129 / SV wild type, heterozygous or homozygous for p53 knockout 6 were used for in situ hybridization. Human primary prostate cancers and lymph node metastatic deposits as well as histologically normal prostate were obtained at radical prostatectomy. The specimens were frozen in liquid nitrogen immediately after surgical removal and 6-μm sections cut with a cryostat. Sections were air-dried and fixed in a solution containing 3 parts 4% paraformaldehyde, 4 parts ethanol and 3 parts glacial acetic acid for 20 min. Anti-sense cRNAs of mRTVP-1 (400 bases) and hRTVP-1 (256 bases) or corresponding sense RNA pr...

example 3

Pro-Apoptotic Activities of mRTVP-1 are Mediated Through the Mitochondrial Pathway

[0072]To analyze the biological activities of mRTVP-1, a series of human prostate cancer cell lines (Tsu-Prl, LNCaP, and PC3) and the human lung cancer cell line, H1299, were infected with AdmRTVP-1 or Adβgal. Western blotting analysis demonstrated high levels of intracellular mRTVP-1 protein by 48 hours after infection.

[0073]As shown in FIG. 4, mRTVP-1 induces apoptosis through mitochondrial death pathway. Apoptosis was determined by annexin V binding and flow cytometry on cells infected with Adβgal (open boxes) or AdmRTVP-1 (closed boxes) at an MOI of 100 as described 38 (FIG. 4a). Protein levels of mRTVP-1 in Tsu-Prl cells were determined by western blotting. Western blotting for bcl family member proteins and cytosolic cytochrome c in LNCaP lysates following transfection with control plasmid pcDNA or pmRTVP-1 (FIG. 4b). Relative caspase activity was determined by densitometric analysis of western b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Therapeuticaaaaaaaaaa
Immunogenicityaaaaaaaaaa
Login to view more

Abstract

This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response. Accordingly, p53 was linked with suppression of metastasis through its induction of mRTVP-1, which can concurrently induce apoptosis, suppress angiogenesis and stimulate an antitumor immune response. Thus, the invention includes compositions and methods, based on RTVP nucleic acid, polypeptides, and antibodies, for use in the treatment, prevention and detection of neoplastic disease and, specifically, metastatic prostatic neoplasia.

Description

REFERENCE TO RELATED APPLICATIONS[0001]This patent application is a divisional of United States Patent Application, entitled RTVP Based Compositions and Methods for the Treatment of Prostate Cancer, Ser. No. 09 / 876,225, filed Jun. 8, 2001, now abandoned, which is a continuation of United States Provisional Patent Application, entitled p-53 Regulated Gene Encoding p144-3 and p144-3 Protein, Ser. No. 60 / 209,989, filed Jun. 8, 2000.RIGHTS IN THE INVENTION[0002]This invention was made, in part, with United States government support under grant number ROI-50588, awarded by the National Cancer Institute, and also grant number P50-58204, awarded by the National Cancer Institute, Specialized Program or Research Excellence (SPORE), and the United States Government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]1. Field of the Invention[0004]The present invention relates to RTVP genes and associated sequences, to RTVP proteins, and to methods and tools using these sequen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00A61K38/00C07K14/47C07K14/705
CPCC07K14/4747C07K14/705A61K38/00A61K39/00
Inventor THOMPSON, TIMOTHY C.REN, CHENGZHEN
Owner BAYLOR COLLEGE OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap